Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials

European Journal of Cancer

Volumn 42, Issue 7, 2006, Pages 835-845

  de Kort, Susanne Joëlle ^a   Willemse, Pax H B ^b   Habraken, Jolanda M ^a   de Haes, Hanneke C J M ^a   Willems, Dick L ^a   Richel, Dick J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advanced colorectal cancer; Chemotherapy; Quality of life; Review; Survival gain; Toxicity

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELL EXTRACT; CYCLOPHOSPHAMIDE; ESCHERICHIA COLI EXTRACT; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; HYDRAZINE SULFATE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; RALTITREXED; TRIMETREXATE; UFT; UNCLASSIFIED DRUG; YTTRIUM 90;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE TOXICITY; ADVANCED CANCER; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CATHETER; CHEMOTHERAPY INDUCED EMESIS; CHRONOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LEUKOPENIA; LIFE EXPECTANCY; LIFESPAN; LIVER TOXICITY; LONG TERM CARE; MEDICAL DECISION MAKING; MEDLINE; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PUMP; QUALITY OF LIFE; SENSORY DYSFUNCTION; STOMATITIS; SYMPTOM; SYSTEMIC THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; META ANALYSIS; METHODOLOGY; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33745298104     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.10.026     Document Type: Article

References (39)

1. Porzsolt F., and Tannock I. Goals of palliative cancer therapy. J Clin Oncol 11 (1993) 378-381
2. Dutch Health Council. Palliative chemotherapy; 2003. Report No.: 18.
3. Verweij J., de Mulder P.H., and Pinedo H.M. The Dutch Health Council report on palliative chemotherapy: possible confusion on ideas. Ned Tijdschr Geneeskd 148 (2004) 651-654
4. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. J Clin Oncol 1992;10:904-11.
5. Efficace F., Bottomley A., Vanvoorden V., et al. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 40 (2004) 187-197
6. Wilson I.B., and Cleary P.D. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273 (1995) 59-65
7. Buyse M., Burykowski K., Carroll K., et al. Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: an analysis of 3159 patients randomized in 11 trials. J Clin Oncol 23 (2005) 249S
8. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. New Engl J Med 352 (2005) 476-487
9. Van Kleffens T., Van Baarsen B., Hoekman K., et al. Clarifying the term 'palliative' in clinical oncology. Eur J Cancer Care (Engl) 13 (2004) 263-271
10. Sepulveda C., Marlin A., Yoshida T., et al. Palliative care: the World Health Organization's global perspective. J Pain Symptom Manage 24 (2002) 91-96
11. Caudry M., Bonnel C., Floquet A., et al. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 18 (1995) 118-125
12. Earlam S., Glover C., Davies M., et al. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 15 (1997) 2022-2029
13. Sobrero A., Zaniboni A., Frassineti G.L., et al. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers. Ann Oncol 11 (2000) 1413-1420
14. Carmichael J., Popiela T., Radstone D., et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3617-3627
15. Douillard J.Y., Hoff P.M., Skillings J.R., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 (2002) 3605-3616
16. Kohne C.H., Wils J., Lorenz M., et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21 (2003) 3721-3728
17. Price T.J., Ross P.J., Hickish T., et al. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 3 (2004) 235-242
18. Hill M., Norman A., Cunningham D., et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumour response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 13 (1995) 2317-2323
19. Seymour M.T., Slevin M.L., Kerr D.J., et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 14 (1996) 2280-2288
20. Ross P., Norman A., Cunningham D., et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8 (1997) 995-1001
21. Comella P., De Vita F., Mancarella S., et al. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 11 (2000) 1323-1333
22. De Gramont, Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
23. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
24. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med 343 (2000) 905-914
25. Unger C., Haring B., Kruse A., et al. Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. Arzneimittelforschung 51 (2001) 332-338
26. Blanke C.D., Shultz J., Cox J., et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 13 (2002) 87-91
27. Punt C.J., Keizer H.J., Douma J., et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 13 (2002) 81-86
28. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350 (2004) 2335-2342
29. Allen-Mersh T.G., Earlam S., Fordy C., et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344 (1994) 1255-1260
30. Loprinzi C.L., Kuross S.A., O'Fallon J.R., et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12 (1994) 1121-1125
31. Cunningham D., Zalcberg J.R., Rath U., et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer 31A (1995) 1945-1954
32. Cocconi G., Cunningham D., Van Cutsem E., et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 16 (1998) 2943-2952
33. Maughan T.S., James R.D., Kerr D.J., et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359 (2002) 1555-1563
34. Fuchs C.S., Moore M.R., Harker G., et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21 (2003) 807-814
35. Lal R., Dickson J., Cunningham D., et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 22 (2004) 3023-3031
36. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
37. Rougier P., Van C.E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 (1998) 1407-1412
38. Rougier P., et al. Erratum. Lancet 352 (1998) 1634
39. Gray B., van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12 (2001) 1711-1720